Fatty acid oxidation fuels agonist‐induced platelet activation and thrombus formation: Targeting β‐oxidation of fatty acids as an effective anti‐platelet strategy

Abstract Platelet mitochondria possess remarkable plasticity for oxidation of energy substrates, where metabolic dependency on glucose or fatty acids is higher than glutamine. Since platelets metabolize nearly the entire pool of glucose to lactate rather than fluxing through mitochondrial tricarboxylic acid cycle, we posit that majority of mitochondrial ATP, which is essential for platelet granule secretion and thrombus formation, is sourced from oxidation of fatty acids. We performed a comprehensive analysis of bioenergetics and function of stimulated platelets in the presence of etomoxir, trimetazidine and oxfenicine, three pharmacologically distinct inhibitors of β‐oxidation. Each of them significantly impaired oxidative phosphorylation in unstimulated as well as thrombin‐stimulated platelets leading to a small but consistent drop in ATP level in activated cells due to a lack of compensation from glycolytic ATP. Trimetazidine and oxfenicine attenuated platelet aggregation, P‐selectin externalization and integrin α IIb β 3 activation. Both etomoxir and trimetazidine impeded agonist‐induced dense granule release and platelet thrombus formation on collagen under arterial shear. The effect of inhibitors on platelet aggregation and dense granule release was dose‐ and incubation time‐ dependent with significant inhibition at higher doses and prolonged incubation times. Neither of the inhibitors could protect mice from collagen‐epinephrine‐induced pulmonary embolism or prolong mouse tail bleeding times. However, mice pre‐administered with etomoxir, trimetazidine and oxfenicine were protected from ferric chloride‐induced mesenteric thrombosis. In conclusion, β‐oxidation of fatty acids sustains ATP level in stimulated platelets and is therefore essential for energy‐intensive agonist‐induced platelet responses. Thus, fatty acid oxidation may constitute an attractive therapeutic target for novel antiplatelet agents.